Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gongwin Biopharm Holdings Co Ltd stock PB Ratio (=5.11) is close to 2-year high of 5.61.
The historical rank and industry rank for Gongwin Biopharm Holdings Co's PB Ratio or its related term are showing as below:
ROCO:6617'
s PB Ratio Range Over the Past 10 Years
Min: 3.02 Med: 4.85 Max: 25.76
Current: 4.84
During the past 13 years, Gongwin Biopharm Holdings Co's highest PB Ratio was 25.76. The lowest was 3.02. And the median was 4.85.
ROCO:6617's PB Ratio is ranked worse than 69.24% of 1229
companies
in the Biotechnology industry
Industry Median: 2.79
vs ROCO:6617: 4.84
During the past 12 months, Gongwin Biopharm Holdings Co's average Book Value Per Share Growth Rate was -16.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 18.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 21.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 15.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Gongwin Biopharm Holdings Co was 400.20% per year. The lowest was -2.40% per year. And the median was 20.65% per year.
Back to Basics: PB Ratio
Gongwin Biopharm Holdings Co (ROCO:6617) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Gongwin Biopharm Holdings Co PB Ratio Related Terms
Gongwin Biopharm Holdings Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6617 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Gongwin Biopharm Holdings Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gongwin Biopharm Holdings Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gongwin Biopharm Holdings Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Gongwin Biopharm Holdings Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Gongwin Biopharm Holdings Co (ROCO:6617) has a PB Ratio of 4.99 as of Jul. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Gongwin Biopharm Holdings Co and its competitors. This is near median its historical median of 4.85. Over the past decade, Gongwin Biopharm Holdings Co's PB Ratio has ranged from 3.02 to 25.76. According to the industry distribution chart, Gongwin Biopharm Holdings Co ranks #851 out of 1229 companies in the Biotechnology industry, placing it in the top 69.2%.
Is Gongwin Biopharm Holdings Co's PB Ratio too high?
Gongwin Biopharm Holdings Co's current PB Ratio of 4.99 is near median its 10-year median of 4.85. Over the past 10 years, this metric has ranged from a low of 3.02 to a high of 25.76. The Biotechnology industry median PB Ratio is 2.79. Gongwin Biopharm Holdings Co's value of 4.99 is 78.9% above this industry median. Based on the distribution chart, Gongwin Biopharm Holdings Co ranks #851 out of 1229 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Gongwin Biopharm Holdings Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gongwin Biopharm Holdings Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gongwin Biopharm Holdings Co ranks #851 out of 1229 companies for PB Ratio. This places Gongwin Biopharm Holdings Co in the lower half of its industry. The industry median PB Ratio is 2.79. Gongwin Biopharm Holdings Co's value of 4.99 is 78.9% above this benchmark. Historically, Gongwin Biopharm Holdings Co's own PB Ratio has ranged from 3.02 to 25.76 over the past decade. While the company's 10-year median is 4.85 vs. the industry median of 2.79, Gongwin Biopharm Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gongwin Biopharm Holdings Co's current PB Ratio of 4.99 is 78.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Gongwin Biopharm Holdings Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gongwin Biopharm Holdings Co's current PB Ratio is 4.99, which is near median its own 10-year median of 4.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gongwin Biopharm Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Gongwin Biopharm Holdings Co (ROCO:6617) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$151.75, compared to a current price of NT$103.00 — trading 32.1% below its estimated fair value. The current PB Ratio is 4.99, which is near median its 10-year median of 4.85 and 78.9% above the Biotechnology industry median of 2.79. Gongwin Biopharm Holdings Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Gongwin Biopharm Holdings Co (ROCO:6617), the current PB Ratio is 4.99 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gongwin Biopharm Holdings Co (ROCO:6617) Overvalued in 2026?
Based on GuruFocus' analysis, Gongwin Biopharm Holdings Co stock appears to be undervalued.
The current stock price of NT$103.00 is trading 32.1% below its estimated GF Value™ of NT$151.75.
GuruFocus considers Gongwin Biopharm Holdings Co to be Significantly Undervalued.
Key valuation signals for ROCO:6617:
PB Ratio: 4.99 (near median its 10-year median of 4.85)
GF Value™: NT$151.75 vs. price of NT$103.00 (32.1% below fair value)
Industry Position: 78.9% above the Biotechnology median (#851 of 1229)
No single metric tells the full story. See the ROCO:6617 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gongwin Biopharm Holdings Co Ltd is a Taiwan-based biopharmaceutical company focused on developing novel anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma. The Group includes pharmaceutical research and development, drug testing, pharmaceutical technology consulting, biotechnology services, technology transfer, and the sale of new drugs.
70GF Score
Get the complete analysis for ROCO:6617
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6617 has been successfully added to your 
